This paper summarizes Professor DING Ying's clinical experience in the treatment of systemic lupus erythematosus （SLE） through differentiation of three states， yin fire， latent fire， and fire toxin. It is proposed that fire pathogenic factors constitute a key pathological element running throughout the entire disease course of SLE. The evolution of its pathogenesis centers on these three states， spleen-kidney deficiency with the initial emergence of yin fire as the onset of disease， damage to yin by medicinal toxicity with internal blazing of latent fire as the driver of disease progression， and the interlocking of blood stasis and heat with intense scorching by fire toxin as the critical factor leading to severe and life-threatening conditions. Corresponding to these three stages， targeted prescriptions are formulated， Jiuwei Yishen Formulation （九味益肾方） to tonify the spleen and kidney， raise yang， and disperse fire； Ziyin Xiehuo Decoction （滋阴泄火汤） to nourish yin and fluids while clearing latent fire； and Santeng Changluo Jiedu Decoction （三藤畅络解毒汤） to dispel blood stasis， unblock the collaterals， detoxify， and restrain fire. This staged and integrated therapeutic strategy aims to address both root and branch and to achieve overall regulation， providing valuable guidance for the clinical differentiation and treatment of SLE.

ObjectiveTo analyze the annual publication volume， prolific research institutions， and research hotspots in the field of shared decision-making （SDM） by utilizing CiteSpace software based on a literature review， predicting the future research focus and development direction in this area. MethodsAn advanced search was conducted in the China National Knowledge Infrastructure （CNKI） and the Web of Science Core Collection databases， with the search timeframe limited to 2004—2024. Scientific knowledge mapping analysis was performed using CiteSpace software. ResultsFrom 2004 to 2024， the volume of publications on SDM research has shown an increasing trend both domestically and internationally. In China， SDM research was mainly focused on nursing， oncology， and other fields， whereas internationally， the emphasis was on patient participation， risk communication， and the application of decision-making support tools. In China， research institutions were primarily nursing schools and specific departments in affiliated hospitals， while internationally， SDM research was concentrated in North America. Keyword analysis showed that the research hotspots in China have gradually shifted from technical topics such as decision-making trees to the practical application of patient participation and decision-making support tools， while international research has earlier moved into the areas of SDM and artificial intelligence-supported decision-making tools. ConclusionThe research hotspots of SDM， both domestically and internationally， have gradually shifted from theoretical exploration to clinical practice and technological applications. In the future， with the deeper integration of artificial intelligence and big data technologies， SDM research in China will focus more on optimizing decision-making support systems and enhancing patient participation. Promoting the localization of SDM practices， fostering multidisciplinary collaboration， and strengthening policy support will be key directions for future research.

The interaction between m⁶A-methylated RNA and chromatin modification remains largely unknown. We found that targeted inhibition of bromodomain-containing protein 4 (BRD4) by siRNA or its inhibitor (JQ1) significantly decreases mRNA m⁶A levels and suppresses the malignancy of breast cancer (BC) cells via increased expression of demethylase AlkB homolog 5 (ALKBH5). Mechanistically, inhibition of BRD4 increases the mRNA stability of ALKBH5 via enhanced binding between its 3' untranslated regions (3'UTRs) with RNA-binding protein RALY. Further, BRD4 serves as a scaffold for ubiquitin enzymes tripartite motif containing-21 (TRIM21) and ALKBH5, resulting in the ubiquitination and degradation of ALKBH5 protein. JQ1-increased ALKBH5 then demethylates mRNA of extra spindle pole bodies like 1 (ESPL1) and reduces binding between ESPL1 mRNA and m⁶A reader insulin like growth factor 2 mRNA binding protein 3 (IGF2BP3), leading to decay of ESPL1 mRNA. Animal and clinical studies confirm a critical role of BRD4/ALKBH5/ESPL1 pathway in BC progression. Further, our study sheds light on the crosstalks between histone modification and RNA methylation.

Objective To retrieve the anticoagulation management related evidences in postoperative patients with heart valve operation to provide an evidence-based basis for medical professionals conducting the antithrombotic therapy in postoperative patients with heart valve operation.Methods The related evidences of anticoagulation management after heart valve surgery were retrieved from major databases and websites at home and abroad based on the"6S"evidence resource pyramid modeling system.The retrieval time was from January 1,2017 to February 29,2024.Two researchers trained by evidence-based care evaluated the quality of the literatures and extracted the relevant evidences meeting the criteria by combining with clinical situation.Results A total of 12 literatures were included,including 5 guidelines,4 clinical practices and 3 expert consen-sus.Thirty pieces of best evidences were summarized in eight aspects:contraindications,postoperative an-tithrombotic regimens,warfarin use method,vitamin K use precautions,daily life precautions,anticoagulation complications,long term perioperative anticoagulation bridging and complicating pregnancy.Conclusion The evidences summarized in this study could provide a reference for standardizing anticoagulation management in postoperative pa-tients with heart valve operation and for clinical healthcare workers in order to standardize the anticoagulation therapy after heart valve replacement and reduce the occurrence of anticoagulation-related complications.

BACKGROUND: Pulmonary arterial hypertension (PAH) presents a significant health burden in Asia and remains a critical challenge. This study aims to delineate the PAH burden in Asia from 1990 to 2021. METHODS: Using the latest data from the Global Burden of Disease 2021, we evaluated and analyzed the distributions and patterns of PAH disease burden among various age groups, sexes, regions, and countries in Asia. Additionally, we examined the associations between PAH disease burden and key health system indicators, including the socio-demographic index (SDI) and the universal health coverage (UHC) index. RESULTS: In 2021, there were 25,989 new PAH cases, 103,382 existing cases, 13,909 PAH-associated deaths, and 385,755 DALYs attributed to PAH in Asia, which accounted for approximately 60% of global PAH cases. The age-standardized rates (ASRs) for prevalence and deaths were 2.05 (95% uncertainty interval [UI]: 1.66-2.52) per 100,000 population and 0.31 (95% UI: 0.23-0.38) per 100,000 population, respectively. From 1990 to 2021, Asia reported the lowest ASRs for PAH prevalence but the highest ASRs for deaths compared to other continents. While the ASRs for prevalence increased slightly, ASRs for mortality and DALYs decreased over time. This increasing burden of PAH was primarily driven by population growth and aging. The burden was especially pronounced among individuals aged ≥60 years and <9 years, who collectively accounted for the majority of deaths and DALYs. Moreover, higher SDI and UHC levels were linked to reduced incidence, but higher prevalence rates. CONCLUSIONS Although progress has been made in reducing PAH-related mortality and DALYs, the disease continues to impose a substantial burden in Asia, particularly among older adults and young children. Region-specific health policies should focus on improving early diagnosis, expanding access to treatment, and effectively addressing the growing PAH burden in the region.
Humans ; Global Burden of Disease ; Male ; Female ; Middle Aged ; Adult ; Asia/epidemiology* ; Prevalence ; Aged ; Pulmonary Arterial Hypertension/mortality* ; Adolescent ; Young Adult ; Child ; Child, Preschool ; Infant ; Hypertension, Pulmonary/epidemiology*

Objective:To explore the potent effects of denatonium benzoate(DB)on Mas-related G protein-coupled receptor-B2(MrgprB2)-mediated rat mast cell degranulation.Methods:RBL-2H3 cells were treated with DB overnight,before challenged with MrgprB2 ligands substance P(SP).The release of β-hex from MrgprB2-activated RBL-2H3 was detected by substrate method.Detec-tion of LTC4,IL-6,TNF-α and cPLA2 activity were performed by ELISA.The Ca2+influx and the expression of RBL-2H3 MrgprB2 re-ceptors were measured by fluorescence assay.Results:The results showed 10 μmol/L,50 μmol/L,80 μmol/L,100 μmol/L DB treat-ments promoted β-hex and LTC4 releases from activated RBL-2H3,accompanied by increased Ca2+mobilization and cPLA2 activa-tion.DB treatments did not affect IL-6 and TNF-α LTC4 releases in MrgprB2-activated RBL-2H3,as well as the levels of MrgprB2 ex-pression in mast cells.Conclusion:Taken together,DB enhanced the MrgprB2-mediated RBL-2H3 degranulation in vitro,probably by up-regulating Ca2+mobilization in activated cells.

Objective To retrieve,evaluate and summarise the relevant evidence in non-pharmacological management of venous thromboembolism in patients with haemorrhagic stroke during perioperative period so as to provide references for clinical practice. Methods According to the "6S" evidence pyramid mode,evidence was retrieved from top to bottom across databases such as BMJ Best Practice,UpToDate,JBI Evidence-Based Healthcare Centre,the National Guideline Clearinghouse (NGC),the National Institute for Health and Care Excellence (NICE),the Scottish Intercollegiate Guidelines Network (SIGN),the Registered Nurses' Association of Ontario (RNAO) guidelines network,the Canadian Heart and Stroke Foundation (HSF),the American Heart Association/American Stroke Association (AHA/ASA),the Neuro-Critical Care Society (NCS),the European Stroke Organization (ESO),Cochrane Library,PubMed,Medline,CNKI,Web of Science,Embase,the China Biomedical Literature Database,Wanfang Data,Medlive,VIP,and the Chinese Medical Journal Full-Text Database. The search focused on non-pharmacological management of perioperative venous thromboembolism in haemorrhagic stroke patients,including guidelines for clinical practice,expert consensus,systematic reviews and evidence summaries. The searched literatrue was from the inception of the databases to April 11th,2024. Two researchers independently evaluated the quality of the literature,extracted,integrated and summarised the best evidences. Results A total of 23 articles were included,comprising 12 guidelines,5 systematic reviews,4 expert consensuses and 2 evidence summaries. Thirty-one pieces of the best evidence were summarised and integrated into 5 topics,including multidisciplinary teamwork,risk assessment and screening,basic prevention,mechanical prophylaxis and health education. Conclusion This study has summarised the best evidence for non-pharmacological management of venous thromboembolism in patients with haemorrhagic stroke during the perioperative period. It provides evidence-based references for clinical medical staff to prevent and manage venous thromboembolism in patients with hemorrhagic stroke during perioperative period.

Objective To retrieve,evaluate and summarise the relevant evidence in non-pharmacological management of venous thromboembolism in patients with haemorrhagic stroke during perioperative period so as to provide references for clinical practice. Methods According to the "6S" evidence pyramid mode,evidence was retrieved from top to bottom across databases such as BMJ Best Practice,UpToDate,JBI Evidence-Based Healthcare Centre,the National Guideline Clearinghouse (NGC),the National Institute for Health and Care Excellence (NICE),the Scottish Intercollegiate Guidelines Network (SIGN),the Registered Nurses' Association of Ontario (RNAO) guidelines network,the Canadian Heart and Stroke Foundation (HSF),the American Heart Association/American Stroke Association (AHA/ASA),the Neuro-Critical Care Society (NCS),the European Stroke Organization (ESO),Cochrane Library,PubMed,Medline,CNKI,Web of Science,Embase,the China Biomedical Literature Database,Wanfang Data,Medlive,VIP,and the Chinese Medical Journal Full-Text Database. The search focused on non-pharmacological management of perioperative venous thromboembolism in haemorrhagic stroke patients,including guidelines for clinical practice,expert consensus,systematic reviews and evidence summaries. The searched literatrue was from the inception of the databases to April 11th,2024. Two researchers independently evaluated the quality of the literature,extracted,integrated and summarised the best evidences. Results A total of 23 articles were included,comprising 12 guidelines,5 systematic reviews,4 expert consensuses and 2 evidence summaries. Thirty-one pieces of the best evidence were summarised and integrated into 5 topics,including multidisciplinary teamwork,risk assessment and screening,basic prevention,mechanical prophylaxis and health education. Conclusion This study has summarised the best evidence for non-pharmacological management of venous thromboembolism in patients with haemorrhagic stroke during the perioperative period. It provides evidence-based references for clinical medical staff to prevent and manage venous thromboembolism in patients with hemorrhagic stroke during perioperative period.

Pancreatic cancer is a disease with a high fatality rate， with a five-year survival rate of no more than 10% and a significantly increasing annual mortality rate. The common pathogenesis factors of pancreatic cancer are family inheritance， diet， pancreatitis， obesity， etc.， among which， family inheritance of pancreatic cancer is the main reason， and about 7%-10% of patients have family inheritance. Surgery is an effective way to treat pancreatic cancer in patients and improve their survival， but most people are diagnosed with pancreatic cancer at intermediate and advanced stages and lose the opportunity for surgical treatment. Therefore， radiotherapy， interventional therapy， supportive treatment， immunotherapy， and other treatments are used clinically to relieve symptoms and prolong the survival of patients. The commonly used clinical drug is gemcitabine. Although it can inhibit tumor growth and improve the condition， it can bring side effects such as bone marrow suppression， rash， digestive tract side effects， and drug resistance. The damage of these side effects to the human body is systemic. Chinese medicine can be used alone or in combination with other treatment methods to reduce the toxic and side effects of chemotherapy， restore the physical energy of patients， and reduce its related complications. Chinese medicine contains a large number of active ingredients， including alkaloids， flavonoids， saponins， phenolic acids， and organic acids， with anti-inflammatory， anti-viral， anti-tumor， and other curative effects. Many clinical studies of traditional Chinese medicine （TCM） on cancers have verified that TCM plays a positive role in tumor prevention and treatment， especially in improving and controlling clinical symptoms， and also plays a good detoxification effect on radiotherapy and chemotherapy， with good results achieved in improving bone marrow suppression， improving immunity， improving quality of life， and prolonging survival. This paper reviewed the anti-pancreatic cancer mechanism of Chinese medicine monomers based on literature in China and abroad， aiming to provide new potential drug candidates for the treatment of pancreatic cancer.

The symptoms of pulmonary nodules are insidious,with inflammatory nodules,inflammatory granuloma,early invasive cancer and lung cancer,and the clinical differential diagnosis is still difficult.Regular CT follow-up observation of most pulmonary nodules provides a"window period"for TCM Intervention in pulmonary nodules.From the aspects of external cold attacking the lung,dense cold and humid geographical environment,cold diet,summer air conditioning,etc.,this paper considers that the soaking of cold pathogenic factors is the basic cause of the formation of pulmonary nodules,and cold phlegm are the basic pathogenesis of pulmonary nodules.The clinical manifestations of cold phlegm in pulmonary nodules are summarized from the two actual situations that can be distinguished from clinical symptoms and no symptoms.It is proposed that Mahuang Fuzi Xixin Decoction and Sanzi Yangqin decoction are the basic formulas,Discussion on the treatment of pulmonary nodules by warming yang and dispelling cold to cure the root cause,eliminating phlegm and softening hard mass to treat the symptoms;Improve the ability of TCM diagnosis and treatment of pulmonary nodules.